暗記メーカー
ログイン
Pharmacokinetics. (1.0)
  • Quinn Karylle Fuentes

  • 問題数 86 • 1/28/2024

    記憶度

    完璧

    12

    覚えた

    32

    うろ覚え

    0

    苦手

    0

    未解答

    0

    アカウント登録して、解答結果を保存しよう

    問題一覧

  • 1

    What are the 2 branches of pharmacotherapeutics.

    Pharmacokinetics and Pharmacodynamics.

  • 2

    What are the parts of pharmacokinetics.

    Absorption, Distribution and Elimination.

  • 3

    What are the branch of pharmacodynamics

    Systemic effect and Cellular effect

  • 4

    In what century did materia medica develop?

    1st century.

  • 5

    It is science of drug preparation and medical use of drugs began to develop as the precursor of pharmacology

    De materia medica.

  • 6

    He is the author of de materia medica.

    Pedanius dioscorides.

  • 7

    used to prepare all sort of strange concoctions, including those of herbs, in order to treat their patients.

    Apothecaries

  • 8

    What century did Some apothecaries decided they had no interest in treating patients. and they were more interested in preparing medical compounds instead

    18th century

  • 9

    Who is the father of pharmacology.

    Oswald Schmiedeberg

  • 10

    He came along that pharmacology became a true and distinct scientific branch of its own in a big way.

    Oswald Schmiedeberg

  • 11

    He studied the pharmacology of various compounds, including chloroform, and published an important text called the Outline of Pharmacology

    Oswald Schmiedeberg

  • 12

    Advances in chemistry and the further development of physiology laid the foundation needed for understanding how drugs work at the organ and tissue levels.

    Advancement in Pharmacology

  • 13

    The relation of the individual’s genetic makeup to his or her response to specific drugs—is close to becoming a practical area of therapy

    Pharmacogenomics

  • 14

    In what century did pharmacogenomic discover.

    20th century

  • 15

    This field of study suggest that our genetic make up can affect our response to a certain drug(T/F)

    True.

  • 16

    common use include • inorganic ions • nonpeptide organic molecules • small peptides and proteins • nucleic acids • lipids and • carbohydrates.

    Drugs.

  • 17

    Drugs used for?

    Diagnosis, Mitigation, Prevention and Cure of diseases.

  • 18

    It is a chemical compound of synthetic, semisynthetic, natural or biological origin which interacts with human or animal cells

    Drugs.

  • 19

    Almost all the several thousand drugs currently available can be arranged into about 70 groups

    True.

  • 20

    Many of the drugs within each group are very different in pharmacodynamic actions and in their pharmacokinetic properties as well.

    False.

  • 21

    For most groups, one or more prototype drugs can be identified that typify the most important characteristics of the group.

    True.

  • 22

    Sizes from MW 7 (Lithium) to over MW 50,000 (thrombolytic enzymes, other proteins)

    Size and molecular weight

  • 23

    Majority of drugs have MW between 100 and 1000.

    True.

  • 24

    which usually result in irreversible action.

    Covalent bond

  • 25

    Somewhat weaker (between a cation and an anion)

    Electrostatic bonds.

  • 26

    Much weaker interactions (hydrogen bond, van der Waals interactions, and hydrophobic bonds)

    True.

  • 27

    The shape of a drug molecule must be such as to permit binding to its receptor site via the bonds

    Drug shape.

  • 28

    The drug’s shape is complementary to that of the receptor site in the same way that a key is complementary to a lock.

    Drug shape.

  • 29

    Compounds that have the same chemical formula but different in structure or spatial arrangement.

    Chirality.

  • 30

    Alter or modulate the normal physiologic functions Interaction of drug molecules and cellular components (receptor) alter the functions of the latter.

    Functional modifier

  • 31

    Supplement endogenous substances that are lacking or deficient in the body

    Replenishers

  • 32

    used to determine the presence or absence of a condition/disease

    Diagnostic agent.

  • 33

    Used to kill or inhibit growth of cells considered as foreign to the body

    Chemotherapeutics.

  • 34

    Who discover and follows the principle of “selective toxicity” (The property of certain chemicals to kill one type of organism while not harming another.)

    Paul ehrlich

  • 35

    The study of how drugs move into, through and out of the body including delivery to their target sites; deals with ADME

    Pharmacokinetics

  • 36

    the drug’s uptake from the site of administration to the systemic circulation

    Absorption

  • 37

    the drug’s movement to various sites after entering systemic circulation

    Distribution

  • 38

    the drug’s conversion to metabolite

    Metabolism

  • 39

    the drug’s removal from the body

    Excretion

  • 40

    The release of active ingredient from its dosage form

    Liberation

  • 41

    rate-limiting step in absorption of solid dosage forms and consequently onset, intensity, and duration of action of the drug.

    Liberation

  • 42

    What are the expections in liberation.

    Oral, Parenteral and Transdermal.

  • 43

    dissolve much readily when compared to the drugs in its free form

    Salt form.

  • 44

    Factors that influence the dissolution rate:

    Crystal form or amorphous drug forms.

  • 45

    Choramphenicol palmitate is inactive in crystalline form but when it is administered in amorphous form, absorption in the GIT is rapid and with good therapeutic response.

    True.

  • 46

    100% amorphous

    Semilente

  • 47

    30% amorphous and 70% crystalline

    Lente

  • 48

    (100% crystalline)

    Ultralente

  • 49

    The proportion of a drug that is delivered to its site of action in the body.

    Bioavailability

  • 50

    High­ dose = ­ high drug absorption

    True.

  • 51

    High blood supply = greater extent/ faster absorption

    True.

  • 52

    The large surface area of the gastro-intestinal tract is due to the presence of macrovilli and microvilli in small intestines (Duodenum)

    True.

  • 53

    Skin (Caucasian Adult)

    1.73 sq. m

  • 54

    Lungs

    70 sq. m

  • 55

    Gastro-intestinal tract

    120-200 sq. m

  • 56

    Essential organ for weakly basic drugs

    Intestine

  • 57

    Essential for absorption of weakly acidic drugs

    Stomach

  • 58

    Highly acidic (pH 1.5-2) (pH 2-6; Fasting ph.

    Stomach

  • 59

    Covered with thick mucus layer

    Stomach

  • 60

    Has villi, large surface area

    Intestine

  • 61

    Short surface area

    Stomach

  • 62

    Not good as an absorption site

    Stomach

  • 63

    Good for absorption

    Intestine

  • 64

    has the greatest capacity for the absorption of drugs from the GI tract

    Duodenum

  • 65

    some drugs are partially metabolized in the liver or portal vein before passing into circulatory system

    First pass effect

  • 66

    some drugs travel intact through the biliary tract after initial absorption and are then reabsorbed into bloodstream through the intestine.

    Enterohepatic recycling

  • 67

    A drug’s route of administration affects its rate and extent of absorption. (T/F)

    True.

  • 68

    moving material in and out of the cell

    Transport mechanism

  • 69

    movement of molecules based on the differences in the concentration across 2 region

    Diffusion

  • 70

    molecules are transported by the movement of a liquid or a gaseous vehicle

    Convection

  • 71

    Process of drug movement across the cell

    Transcellular

  • 72

    Process of drug movement that goes through gaps or tight junction between cell

    Paracellular

  • 73

    higher concentration to lower concentration movement of small lipophilic molecule along a conc. Gradient

    Passive transport

  • 74

    This law states that the rate of diffusion of a solute molecule through a barrier is proportional to the concentration gradient.

    Ficks first law

  • 75

    This law states that the change in concentration with respect to time at a particular region is proportional to the change in the concentration gradient at that point in the system.

    Ficks second law

  • 76

    A passive process requiring no cellular energy

    Facilitated transport

  • 77

    Drug moves along a concentration gradient and Saturable and structurally selective

    Facilitated transport

  • 78

    From lower concentration to higher concentration “pushing a rock uphill” which requires cellular energy

    Active transport

  • 79

    small drug molecules simply move along with fluid through the pores in cell walls

    Pore transport

  • 80

    MEDIATED through “water-filled pores/channels/aquaporins

    Pore transport

  • 81

    Cell eating.

    Phagocytosis

  • 82

    Cell drinking.

    Pinocytosis

  • 83

    it is a process by which cells absorb molecules (such as proteins) by engulfing them

    Endocytosis

  • 84

    Complex of organic anion with cation

    Ion pair transport

  • 85

    Linkage of ionized drug with oppositely charge ion (neutral complex)

    Ion pair transport

  • 86

    What are the parts of pharmacokinetics.

    Absorption, Distribution and Elimination